Alexander's, Inc.

Alexander's, Inc. (ALX) Market Cap

Alexander's, Inc. has a market capitalization of $1.32B.

Price: $258.59

2.65 (1.04%)

Market Cap: 1.32B

NYSE · time unavailable

CEO: Steven Roth

Sector: Real Estate

Industry: REIT - Retail

IPO Date: 1973-02-21

Website: https://www.alx-inc.com

Alexander's, Inc. (ALX) - Company Information

Market Cap: 1.32B|Sector: Real Estate

Company Profile

Alexander's, Inc. is a real estate investment trust which has seven properties in the greater New York City metropolitan area.

Analyst Sentiment

8%
Underperform

From 1 Active Polls

1Y Forecast: $125.00

▼ -51.7% Potential Upside

Consensus Target Metrics

Low Bound

$125

Median

$125

High Bound

$125

Average

$125

Price & Moving Averages

Loading chart...

🎯 Wall Street Analyst Intelligence Report

1-Year structural target targets, chart projections, and sentiment maps.

Average 1Y Target
$125.00
▼ -51.66% Upside
Low Target
$125.00
-52% Risk
Median Target
$125.00
-52% Mid
High Target
$125.00
-52% Max
Consensus
Buy
1 / 2 Buys

Consensus Trend Projection

Trailing closures vs. 12-month metrics map.

Analyst Vote Distribution

Aggregate institutional coverage sentiment weights.

📊 Historical Valuation Multiples

Real-time Trailing Twelve Month (TTM) momentum side-by-side with discrete quarterly metrics.

Fiscal QuarterTTMQ1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024
Period EndingTrailing 12MMar 31, 2026Dec 31, 2025Sep 30, 2025Jun 30, 2025Mar 31, 2025Dec 31, 2024Sep 30, 2024Jun 30, 2024
Market Cap ($M)1,3211,2131,1191,2041,1571,0741,0271,2441,113
Enterprise Value ($M)2,1902,0821,9342,0191,9451,8571,7911,9911,898
Price to Earnings Ratio (P/E)64.5565.0573.1650.4547.2621.8020.9146.5833.21
Price/Earnings-to-Growth Ratio (PEG)220.6614.1849.5310.89
Price to Sales Ratio (P/S)6.2422.7121.0122.5422.4319.5518.3622.3520.85
Price to Book Ratio (P/B)14.6413.3710.259.387.956.585.816.535.24
Price to Free Cash Flow Ratio (P/FCF)20.46177.9847.78-129.9626.5668.3133.32-247.3296.79
Enterprise Value to Sales (EV/Sales)38.9936.3237.7937.7033.8232.0435.7635.55
Enterprise Value to EBITDA (EV/EBITDA)20.3791.6672.9567.6068.4457.1550.9958.7156.15
Debt to Equity Ratio8.0910.428.648.587.576.766.245.785.63

ALX Growth Runway Model

Standard long term linear growth fade

Multi-Stage Discounted Cash Flow Sandbox

Market Price$258.59
Intrinsic Value$274.45
Market Alignment
Undervalued by 6.1%relative to calculated intrinsic value
9.00%
Exp: 1%1%
i

Growth runway slowdown

This value provides a time window for the growth rate to decline beyond Stage 1 toward the terminal rate. Longer windows are most useful for companies with high growth starting conditions or strong competitive advantages. This option stretches out the growth rate slowdown across 5, 10, or 15-year steps. A high-growth starting condition (exceeding a 25% initial growth rate) automatically applies a curve decay to simulate realistic, rapid market saturation.
i

Terminal growth rate

With long-term inflation between 3-5%, revenue must grow by that baseline to maintain flat real-world market share. This value sets the permanent terminal growth rate to factor into the valuation beyond the growth slowdown runway toward maturity.

3-Stage Financial Runway Horizon

🧠 Perpetuity Horizon Engine (Stage 3: Post-2035)

Terminal FCF Base$0.16B
Perpetuity TV Value$2.98B
Discounted TV (PV)$1.26B
TV Weighting %58.1%
⚠️
Financial Model Disclaimer & Risk Disclosure: This interactive scenario simulator is an educational sandbox provided strictly for informational and analytical research purposes. Core historical financial statements and consensus estimates are sourced directly via Financial Modeling Prep (FMP). All downstream outputs are entirely deterministic, hypothetical projections generated by combining automated mathematical formulas (including linear interpolation and Gaussian bell-curve decay models) with user-selected variables and third-party financial data inputs. Users assume all liability for trading decisions executed based on these sandbox calculations.

📘 Full Research Report

ℹ️

AI-Generated Research: This report is for informational purposes only.

📘 ALEXANDERS REIT INC (ALX) — Investment Overview

🧩 Business Model Overview

ALEXANDERS REIT INC operates as a focused real estate owner with an emphasis on acquiring, leasing, and—critically—redeveloping property in high-demand, supply-constrained markets. The value chain is straightforward: the company secures real estate assets, leases space to tenants under contractual terms, and manages the operational performance of those assets (rent collection, operating expense management, tenant relations). Where the company generates value beyond “rent roll,” it does so through redevelopment and repositioning of space—enhancing the income-producing profile of properties after planning, entitlements, and construction.

Tenant stickiness typically comes from (1) lease commitment periods, (2) the practical difficulty and cost of relocating to an equivalent location, and (3) the capital investment embedded in occupied space (build-out, branding needs, and operational continuity). For a concentrated Manhattan-focused REIT model, the moat is less about “network effects” and more about location scarcity and execution capability.

💰 Revenue Streams & Monetisation Model

Revenue is primarily driven by rental income generated from leased properties. Monetisation occurs through:

  • Base rent and contractual escalations: Recurring revenue supported by lease structures.
  • Recoveries of operating expenses: Often passed through to tenants, which can moderate operating margin volatility.
  • Tenant inducements offset by lease renewals and re-leasing economics: Monetisation is realized when leases roll and the company can reprice based on market conditions and property improvements.
  • Redevelopment and repositioning: Non-linear value creation driven by transforming older assets into higher-rent, higher-quality configurations after completion and leasing.

Margin drivers in this model are property occupancy, the ability to control operating costs, and—when redevelopment is involved—the spread between the ultimate stabilized income and the total development cost (including financing and timing risk).

🧠 Competitive Advantages & Market Positioning

ALX’s competitive position is best understood as a geographic scarcity + redevelopment execution moat. In prime, high-demand urban markets, there are persistent structural constraints on acquiring equivalent sites at reasonable costs, and redevelopment requires specialized approvals, construction partners, and timing discipline. These factors limit “fast follower” capacity.

  • Moat mechanism — Geographic cost advantage (scarcity and access): Prime locations are difficult to replicate. Competitors may own adjacent assets, but they cannot easily substitute comparable supply without materially higher cost or longer entitlement timelines.
  • Moat mechanism — Switching costs (tenant location and lease commitments): Tenants face real friction relocating operations away from a top-tier location, especially when build-outs and operational dependencies exist.
  • Moat mechanism — Execution optionality (redevelopment skill): Value creation depends on translating capital and entitlements into stabilized income, which is harder than writing a business plan—construction complexity and leasing risk are material.

COMPETITIVE BENCHMARKING

  • Vornado Realty Trust (VNO): More diversified exposure across Manhattan office and retail with broader scale. VNO can spread risk across more properties, while ALX’s concentration can create higher idiosyncratic outcomes tied to specific redevelopments and leasing results.
  • SL Green Realty (SLG): Manhattan-heavy office exposure with development activity. SLG’s portfolio scale and leasing mix differ, but both operate in the same constrained Manhattan real estate regime where entitlements and leasing cycles determine outcomes.
  • Macerich (MAC): Retail-property focus, often in suburban or large-format centers rather than purely Manhattan prime sites. Macerich competes for tenants and consumer demand, but the substitution economics differ because the “asset type” and location drivers are not the same as prime dense-city assets.

Compared with these rivals, ALX’s positioning is characterized by concentration and redevelopment-driven value rather than broad portfolio diversification. That increases dispersion of outcomes, but it also concentrates upside when executed well.

🚀 Multi-Year Growth Drivers

  • Redevelopment value realization: Converting older configurations into modern, higher-quality space can lift net operating income and support rent re-leasing economics.
  • Urban demand resilience tied to scarcity: In constrained central markets, supply limitations and high barriers to new comparable development support long-term rental fundamentals.
  • Lease roll strategy and tenant quality: The ability to refinance, re-lease, or upgrade tenant mixes at favorable economics supports compounding cash flow across cycles.
  • Operational discipline: Expense management and capital allocation that prioritizes income-return projects can enhance durability of funds available to investors.

Over a 5–10 year horizon, the addressable opportunity for a concentrated REIT like ALX is primarily tied to how consistently it can convert entitlement and construction work into stabilized occupancy and higher net cash flows, while maintaining balance sheet resilience through property and capital-market cycles.

⚠ Risk Factors to Monitor

  • Capital intensity and timing risk: Redevelopment introduces multi-year uncertainty (construction delays, cost overruns, and leasing timelines).
  • Interest-rate and refinancing risk: REIT profitability and balance-sheet outcomes can be sensitive to the cost of debt and refinancing availability.
  • Tenant concentration and credit risk: A smaller portfolio increases exposure to individual tenant decisions, rent collection quality, and space demand shifts.
  • Regulatory and permitting risk: Zoning, entitlements, building-code requirements, and local regulatory changes can affect project feasibility and economics.
  • Market-cycle vulnerability: Changes in the office/retail leasing environment and investor sentiment toward real estate can pressure valuation and leasing assumptions.

📊 Valuation & Market View

The market typically values real estate companies on net asset value (NAV) and property-level cash flow quality rather than purely on near-term earnings metrics. Common valuation frameworks for this sector include:

  • NAV / asset-based valuation: Expected stabilized income discounted by prevailing cap rate assumptions for the specific property class and location.
  • FFO/normalized cash flow metrics: Reflects recurring operating performance, excluding non-cash items and smoothing property accounting effects.
  • Redevelopment economics: Investors focus on the spread between stabilized rents and all-in development costs, with particular attention to timing and risk-adjusted returns.

Valuation typically moves with (1) interest rates and real estate cap rates, (2) occupancy/lease-up outcomes, and (3) confidence that redevelopment projects will achieve stabilized income on budget.

🔍 Investment Takeaway

ALX is best framed as a concentrated, Manhattan-oriented REIT where the durable advantages come from prime location scarcity, tenant inertia, and redevelopment execution capability. The investment thesis depends on translating redevelopment optionality into stabilized net operating income while maintaining capital discipline through leasing cycles and cost-of-capital changes. For long-term investors, the core question is whether asset-level execution consistently outperforms the risk-adjusted cost of capital embedded in market pricing.


⚠ AI-generated — informational only. Validate using filings before investing.

📰 Market News & Coverage

15 Stories Available

Real-time institutional reporting and market updates for ALX.

globenewswire.com2026-06-01

ALX Oncology to Present at the 2026 Jefferies Global Healthcare Conference in New York

SOUTH SAN FRANCISCO, Calif., June 01, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced that ALX Oncology leadership will participate in a fireside chat presentation at the 2026 Jefferies Global Healthcare Conference in New York.

globenewswire.com2026-05-28

Alexander’s Completes Sale of Rego Park I

PARAMUS, N. J. , May 28, 2026 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) announced today that it has completed the previously announced sale of its Rego Park I property, located in Queens, New York, to Northwell Health, Inc. The gross sales price was $235.

globenewswire.com2026-05-28

Alexander's Completes Sale of Rego Park I

PARAMUS, N.J., May 28, 2026 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) announced today that it has completed the previously announced sale of its Rego Park I property, located in Queens, New York, to Northwell Health, Inc.

forbes.com2026-05-17

The Most Hated High Yields On Wall Street

Let's capitalize on analyst incompetence—and bank yields up to 18.3%, with upside to boot!

marketbeat.com2026-05-08

ALX Oncology Q1 Earnings Call Highlights

ALX Oncology NASDAQ: ALXO executives used the company's first-quarter 2026 earnings call to highlight new clinical data for its lead CD47 blocker, evorpacept, and to provide updates on its EGFR-targeted antibody-drug conjugate program, ALX2004. CEO Jason Lettmann said the quarter featured “continued good execution,” including a February financing and the addition of Jeff Knight as chief development and chief operating officer.

globenewswire.com2026-05-08

ALX Oncology Reports First Quarter 2026 Financial Results and Provides Corporate Update

- Data from Phase 1b/2 trial of evorpacept + zanidatamab presented at ESMO Breast Cancer 2026 showed all patients with confirmed HER2-positive disease and high CD47 expression experienced durable responses to this combination -

globenewswire.com2026-05-07

ALX Oncology's Evorpacept in Combination with Zanidatamab Generates Promising, Durable Response in Patients with Advanced HER2-Positive Breast Cancer and High CD47 Expression

- Data from Phase 1b/2 trial presented at ESMO Breast Cancer 2026 further validate a biomarker-driven development strategy for evorpacept -

zacks.com2026-05-04

Alexander's (ALX) Q1 FFO and Revenues Lag Estimates

Alexander's (ALX) came out with quarterly funds from operations (FFO) of $2.6 per share, missing the Zacks Consensus Estimate of $3.08 per share. This compares to FFO of $4.06 per share a year ago.

gurufocus.com2026-05-01

A Look at Alexander's Inc (ALX) After 3.0% Decline -- GF Value $203.84 vs Price $244.34

On May 01, 2026, Alexander's Inc (ALX) shares fell 3.0%, closing at $244.34. The stock has traded within a 52-week range of $201.28 to $260.84, reflecting some

globenewswire.com2026-04-30

ALX Oncology Announces That CD47 Biomarker Data from Clinical Trial Evaluating Evorpacept + Zanidatamab Combination in Advanced Breast Cancer Will Be Presented at ESMO Breast Cancer 2026

- Company Will Discuss Data and Report First Quarter 2026 Financial Results on May 8 - SOUTH SAN FRANCISCO, Calif., April 30, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. ("ALX Oncology"; Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, today announced that new data from the Phase 1b/2 clinical trial evaluating the company's investigational CD47-inhibitor evorpacept in combination with Jazz Pharmaceuticals' zanidatamab (ZIIHERA®) in heavily pretreated patients with HER2-positive metastatic breast cancer (mBC) will be presented at the ESMO Breast Cancer 2026 Congress in Berlin on May 7.

globenewswire.com2026-04-29

Alexander's Declares Quarterly $4.50 Dividend on Common Shares

PARAMUS, N.J., April 29, 2026 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that its Board of Directors has declared a regular quarterly dividend of $4.50 per share payable on May 29, 2026 to stockholders of record on May 11, 2026.

globenewswire.com2026-04-21

Alexander's Announces First Quarter Earnings Release Date and Vornado Realty Trust Quarterly Conference Call

PARAMUS, N.J., April 21, 2026 (GLOBE NEWSWIRE) -- Alexander's, Inc. (NYSE: ALX) today announced that it will file its quarterly report on Form 10-Q for the quarter ended March 31, 2026 with the U.S. Securities and Exchange Commission and issue its first quarter earnings release on Monday, May  4, 2026, before the New York Stock Exchange opens.

globenewswire.com2026-04-17

ALX Oncology Reports Inducement Grant as permitted by the Nasdaq Listing Rules

SOUTH SAN FRANCISCO, Calif., April 17, 2026 (GLOBE NEWSWIRE) -- ALX Oncology Holdings Inc. (“ALX Oncology,” Nasdaq: ALXO), a clinical-stage biotechnology company advancing a pipeline of novel therapies designed to treat cancer and extend patients' lives, announced that the Compensation Committee of the Board of Directors of ALX Oncology approved the granting of an inducement stock option to purchase a total of 800,000 shares of ALX Oncology's common stock to Jeff Knight, M.P.H., Chief Development and Operating Officer, on April 16, 2026 in connection with the commencement of his employment. Mr. Knight's inducement stock option is subject to the terms of the ALX Oncology Holdings Inc. 2025 Inducement Equity Incentive Plan and related forms of agreements, and was granted as an inducement material to Mr. Knight to enter into employment with ALX Oncology in accordance with Nasdaq Listing Rule 5635(c)(4).

seekingalpha.com2026-04-16

Longleaf Partners Small-Cap Fund Q1 2026 Portfolio Review

Alcoholic beverage company Boston Beer was a contributor for the quarter as industry data improved compared to last year. Children's toy, media, and consumer products creator Mattel was a detractor in the quarter. During the quarter we had no new purchases or exits.

globenewswire.com2026-04-13

ALX Oncology Appoints Jeff Knight as Chief Development and Operating Officer

- Veteran biopharmaceutical and oncology leader brings more than three decades of experience across clinical development, regulatory, and operational execution

📊 AI Financial Analysis

Powered by StockMarketInfo
Earnings Data: Q Ending 2026-03-31

"ALX reported Q1’26 Revenue of $53.41M and Net Income of $4.66M (EPS $0.91). QoQ (vs Q4’25), revenue was essentially flat (+0.30%) while net income rose meaningfully (+21.9%). YoY (vs Q1’25), revenue declined (-2.8%) and net income fell sharply (-62.1%), indicating a weaker earnings conversion versus last year. Profitability was mixed across the four-quarter history: Q1’26 net margin was ~8.7% (down from ~22.4% in Q1’25 and below Q2–Q3’25 levels around ~11.9%+), suggesting margin contraction and higher below-the-line drag (notably interest expense). Gross profit ratio also weakened sharply in Q1’26 compared with prior quarters, consistent with an earnings quality reset. Cash flow remained problematic versus earnings. Operating cash flow in Q1’26 was $2.03M versus net income of $4.66M, and free cash flow was similarly low ($2.03M), while dividends continued ($23.1M paid), implying cash outflows exceeded operating generation for the quarter and contributing to a steep cash decline to $37.8M (from $128.2M in Q4’25). The company still posted strong shareholder momentum: the stock is up 26.8% over 1 year, supporting total return despite the cash build/draw volatility. Note: Balance sheet data show negative cash and equity at quarter-end, so leverage/resilience should be interpreted cautiously."

Revenue Growth

Fair

QoQ revenue +0.30% (53.41M vs 53.26M). YoY revenue -2.8% (53.41M vs 54.92M), indicating mild top-line softness.

Profitability

Caution

Net income QoQ +21.9%, but YoY net income -62.1%. Net margin fell to ~8.7% in Q1’26 from ~22.4% in Q1’25; profitability is contracting over the year.

Cash Flow Quality

Caution

Operating cash flow $2.03M vs net income $4.66M and free cash flow $2.03M. Dividends remain heavy ($23.1M paid in the quarter), leading to cash drawdown.

Leverage & Balance Sheet

Neutral

Reported balance sheet figures at 2026-03-31 show cash and total assets/equity negative (data-quality/format issue likely). Trend-wise, cash dropped sharply QoQ (128.2M to 37.8M), but leverage metrics should be treated cautiously.

Shareholder Returns

Good

Strong price momentum: +26.8% 1Y. Dividend yield is ~1.9% in the latest ratios, though coverage appears stretched given low Q1’26 cash generation.

Analyst Sentiment & Valuation

Neutral

Consensus price target ($125 high/low/median) is far below the current price ($252.15), implying elevated downside in valuation expectations despite positive 1Y momentum.

Disclaimer:This analysis is AI-generated for informational purposes only. Accuracy is not guaranteed and this does not constitute financial advice.

Fundamentals Overview

Loading fundamentals overview...

So What?: Management’s tone is aggressively bullish on New York office fundamentals—tight “better space” availability (~10.7% quickly evaporating; Park Avenue <7%) plus frozen new supply leads them to expect a rent “spike.” They connect this directly to longer-dated earnings growth: 2026 is framed as an improvement period, but the “very significant improvement” is in 2027, as mark-to-market and leasing/backfill benefits flow through. The Q&A pressure, however, exposes the earnings bridge timing risk: 2025 is expected to be slightly lower than 2024 because 2024 benefited from a one-time lease termination income event (304,000 sf at 330 W 34th with WeWork/Amazon). While concessions have not broadly fallen and rents are rising, near-term results are still constrained by higher/steady borrowing costs and GAAP timing (vacancy backfill/lease-up impacts delayed to end-2026). The “bullseye” Penn Two story is strong, but the financial upside is weighted to later years.

AI IconGrowth Catalysts

  • Penn Two leasing momentum: $100+/sf rents and raised building-wide rents (timing for a ~330,000 sf lease described as “short order”)
  • 770 Broadway NYU master lease to be completed by end of February 2025; eliminates ~500,000 sf vacancy and reduces ~$700M debt on that asset
  • 330 West 34th Street: recognized lease termination income tied to a 304,000 sf lease with WeWork on behalf of Amazon (accelerated activity in 2024)
  • Penn Two expected to be ~80% leased by year-end 2025 (management prediction)
  • Portfolio demand/absorption described as broad-based (financial, legal, tech) with multiple expansions/renewals and “concessions neutralized”

Business Development

  • NYU master lease at 770 Broadway (1.1M sf; completion expected by end of month)
  • WeWork (acting on behalf of Amazon) lease termination income associated with a 304,000 sf lease at 330 West 34th Street
  • Bloomberg renewal: early renewed 947,000 sf Bloomberg office lease at 731 Lexington Avenue; pushed expiry out to 2034
  • Alexander’s affiliate (Alexander’s, Inc.) Rego Park tenant moves: Burlington and Marshall moved from Rego One to adjacent Rego Two

AI IconFinancial Highlights

  • Comparable FFO: $2.26/share for full-year 2024 (down vs 2023); cited drivers were lower NOI from known move-outs and higher net interest expense
  • Q4 comparable FFO: $0.61/share vs $0.63/share in Q4 2023; decrease driven by higher net interest expense and lower NOI (non-move-outs), partially offset by lease termination income
  • Lease termination income at 330 West 34th Street (304,000 sf lease with WeWork/Amazon) was the key positive 2024 driver vs earlier expectations
  • Net interest expense: ended lower than initial projection due to short-term rates coming down; guidance notes short-term rates likely to stay around current levels
  • Penn Two incremental yield increased to 10.2% (question references ~+70 bps yield push at Penn Two)
  • Office occupancy: year-end 2024 office occupancy 88.8% (vs 87.5% prior quarter); with pending 770 Broadway master lease, occupancy increases by +330 bps to 92.1%
  • 2025 outlook framing: no formal guidance, but company expects 2025 comparable FFO slightly lower than 2024 (attributed to 2024 one-time lease termination income and GAAP timing/backfilling not occurring until toward end of 2026)

AI IconCapital Funding

  • Debt repayment: repaid at maturity $450M unsecured bonds at 3.5% using cash on balance sheet plus $108M from the credit line
  • 770 Broadway: master lease expected to relieve ~$700M of debt on the asset
  • 1535 Broadway refinancing: to redeem forecasted over $400M of retail JV preferreds; refinancing proceeds described as ~$200M+ coming in
  • Incremental capital proceeds: management expects ~$1B of new cash proceeds (“$700M pay off debt” + ~$200M from 1535 refinancing + additional short-term dispositions to round it up)

AI IconStrategy & Ops

  • Penn Two: described as “more than off and running” (bullseye for large tenants), with 330,000 sf lease to be completed soon and LOI in serious stages for another large HQ tenant; also tenants “battling for space” in 60,000–200,000 sf range
  • Rents: management said they “raised our rents across the entire building” for Penn Two
  • Occupancy timing: first-quarter 2025 occupancy decrease expected due to Penn Two being placed in service; described as temporary with stabilization over the next year into the low 90s
  • Capital markets posture: CMBS “wide open” for large high-quality assets; AAA/overall spreads for 299 Park Ave tightened back to pre-COVID; banks largely on sidelines for new office lending but some beginning to finance smaller deals

AI IconMarket Outlook

  • Rent outlook: management expects “rents to go up significantly next year” and uses “spike” language; Q&A clarified material improvement in 2026 vs “very significant improvement” in 2027
  • Occupancy outlook: 770 Broadway master lease lifts occupancy to 92.1%; Q1 2025 temporarily lower due to Penn Two in service before stabilizing into low 90s
  • Leasing pipeline: 770,000 sf in negotiation plus 1.0M sf master lease with NYU finalized; another 1.3M sf in proposals/negotiations
  • Financing market: short-term rates after prior 100 bps decline likely remain around current levels, keeping borrowing costs “high” (risk to refinancing economics)

AI IconRisks & Headwinds

  • Interest-rate headwind: short-term rates likely to remain around current levels for foreseeable future; long-term rates “have not fallen at all,” cited as part of why new supply is frozen
  • Earnings timing risk (GAAP): 2025 slightly lower comparable FFO; positive GAAP impacts/backfilling of vacancies and Penn One/Penn Two lease-up won’t occur until toward end of 2026, with full positive impact in 2027
  • Lease-up/earnings volatility tied to move-outs: 2024 lower NOI from known move-outs and higher net interest expense; Q4 NOI weaker on non-move-outs
  • No explicit tariffs/macro mitigation stated; the macro/rates discussion focused on rate levels and their effect on supply and borrowing costs

Sentiment: POSITIVE

Note: This summary was synthesized by AI from the ALX Q4 2024 earnings transcript. Financial data is complex; please verify all metrics against official SEC filings before making investment decisions.

📋 Official Regulatory 10-K / 10-Q SEC Filings

Direct authenticated documentation links to audited SEC database reports for ALX.

SEC EDGAR Live Feed
Loading financial data and tables...
📁

SEC Filings (ALX)

© 2026 Stock Market Info — Alexander's, Inc. (ALX) Financial Profile